A share price of CRISPR Therapeutics AG [CRSP] is currently trading at $49.99, up 1.87%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRSP shares have gain 7.71% over the last week, with a monthly amount drifted -12.59%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on August 06, 2024, when Needham reiterated its Buy rating and also revised its price target to $84 from $88. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 02, 2024, and set its price target to $90. Wolfe Research started tracking the stock assigning a Peer Perform rating. TD Cowen downgraded its rating to a Underperform but $30 remained the price target by the analyst firm on December 11, 2023. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 17, 2023. In a note dated September 27, 2023, Mizuho initiated an Buy rating and provided a target price of $82 on this stock.
CRISPR Therapeutics AG experienced fluctuations in its stock price throughout the past year between $37.55 and $91.10. Currently, Wall Street analysts expect the stock to reach $109.58 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $49.99 at the most recent close of the market. An investor can expect a potential return of 119.2% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Trailing Twelve Months sales for CRISPR Therapeutics AG [NASDAQ:CRSP] were 202.23M which represents -99.26% decline. Gross Profit Margin for this corporation currently stands at 0.24% with Operating Profit Margin at -1.76%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.14 and Total Capital is -0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 49.25 points at the first support level, and at 48.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 50.47, and for the 2nd resistance point, it is at 50.96.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CRISPR Therapeutics AG [NASDAQ:CRSP] is 15.73. As well, the Quick Ratio is 15.73, while the Cash Ratio is 3.79. Considering the valuation of this stock, the price to sales ratio is 21.05, the price to book ratio is 2.15.
Transactions by insiders
Recent insider trading involved Bruno Julianne, Chief Operating Officer, that happened on Jun 21 ’24 when 3366.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Apr 15 ’24 to sell 19582.0 shares. Meanwhile, Chief Financial Officer Prasad Raju sold 3524.0 shares on Mar 15 ’24.
